CasNo.573762-62-6,99% up by HPLC 5-Amino-3-(Trifluoromethyl) Picolinonitrile 573762-62-6,(573762-62-6) Suppliers

1 Kilogram	FOB Price:USD 50.0000 -800.0000

Min.Order :1 Kilogram
Purity: 99% up
Payment Terms : L/C,D/A,D/P,T/T

Keywords

5-Amino-3-(Trifluoromethyl) Picolinonitrile apalutamide intermediate apalutamide

Quick Details

Appearance:White powder
Application:Pharmaceutical Intermediates
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:20|Kilogram|Day
Storage:in low tempreture
Transportation:Room temperature

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin

Details:

Product name	5-Amino-3-(trifluoromethyl) picolinonitrile / Apalutamide intermediate
CAS No.	573762-62-6
Molecular Formula	C7H4 F3N3
Molecular Weight	187.124
Quality Standard	98% up by HPLC
Appearance	White powder

Molecular Structure:

Synonyms:	5-Amino-3-(trifluoromethyl)pyridine-2-carbonitrile; 5-Amino-2-cyano-3-(trifluoromethyl)pyridine; 5-Amino-3-(trifluoromethyl)2-cyanopyridine
EINECS:	815-137-9
Density:	1.45±0.1 g/cm3(Predicted)
Boiling Point:	362.2±42.0 °C(Predicted)
PSA:	62.70000
LogP:	2.13548

5-Amino-3-(trifluoromethyl) picolinonitrile is one of key intermediates of apalutamide (N-2).

Function of Apalutamide

As a second-generation nonsteroidal androgen receptor inhibitory drug, apalutamide can prevent the fusion of androgen and receptors, and block the transfer of AR to the nucleus of cancer cells. In addition, apalutamide can also control androgen and promote the growth of cancer cells.

The safety and efficacy of apalutamide are based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer. Patients in the trial received apalutamide or placebo. All patients also received hormone therapy, either with a gonadotropin-releasing hormone (GnRH) analog, or with surgery to lower the amount of testosterone in the body (surgical castration). Median metastasis-free survival was 40.5 months for patients taking apalutamide, compared with 16.2 months for patients taking placebo. From the above experiments, we can see that the effect of apalutamide in the treatment of prostate cancer is very significant.